A phase 1 study of DS-8201a in combination with olaparib in HER2-expressing malignancies (CTEP #10355): Results of module 1 dose escalation

被引：0
|
作者：
Lee, Elizabeth K.
Hendrickson, Andrea E. Wahner
Colon-Otero, Gerardo
Pickett, Cheryl A.
Xiong, Niya
Cheng, Su-Chun
Polak, Madeline
Sawyer, Hannah
Hayes, Martin
Matulonis, Ursula A.
Shapiro, Geoffrey I.
Konstantinopoulos, Panagiotis A.
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2023年 / 22卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-23-B041
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B041
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study
    Meric-Bernstam, Funda
    Beeram, Muralidhar
    Hamilton, Erika
    Oh, Do-Youn
    Hanna, Diana L.
    Kang, Yoon-Koo
    Elimova, Elena
    Chaves, Jorge
    Goodwin, Rachel
    Lee, Jeeyun
    Nabell, Lisle
    Rha, Sun Young
    Mayordomo, Jose
    El-Khoueiry, Anthony
    Pant, Shubham
    Raghav, Kanwal
    Kim, Jin Won
    Patnaik, Amita
    Gray, Todd
    Davies, Rupert
    Ozog, Mark A.
    Woolery, Joseph
    Lee, Keun-Wook
    LANCET ONCOLOGY, 2022, 23 (12): : 1558 - 1570
  • [22] Phase III study of [fam-] trastuzumab deruxtecan (DS-8201a) vs TDM1 for HER2-positive breast cancer
    Verma, S.
    Shahidi, J.
    Lee, C.
    Wang, K.
    Cortes, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [23] Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study (vol 20, pg 827, 2019)
    Shitara, K.
    Iwata, H.
    Takahashi, S.
    LANCET ONCOLOGY, 2019, 20 (06): : E293 - E293
  • [24] Phase 1 dose-escalation study of single-agent ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers
    Beeram, M.
    Hamilton, E.
    Murphy, M. Blum
    Hausman, D.
    Infante, J. R.
    Korn, R.
    Patnaik, A.
    Piha-Paul, S. A.
    Rasco, D.
    Rowse, G.
    Thimmarayappa, J.
    Tolcher, A.
    Meric-Bernstam, F.
    ANNALS OF ONCOLOGY, 2017, 28
  • [25] Phase 1 Dose Escalation Study of MDM2 Inhibitor DS-3032b in Patients with Hematological Malignancies - Preliminary Results
    DiNardo, Courtney D.
    Rosenthal, Joseph
    Andreeff, Michael
    Zernovak, Oleg
    Kumar, Prasanna
    Gajee, Roohi
    Chen, Shuquan
    Rosen, Michael
    Song, Saeheum
    Kochan, Jarema
    Limsakun, Tharin
    Olin, Rebecca
    BLOOD, 2016, 128 (22)
  • [26] Preliminary results of a phase I, first-in-human, dose escalation study of IMM2902 in patients with HER2-expressing advanced solid tumors
    Meng, Yanchun
    Zhang, Jian
    Zhao, Chuanhua
    Cheng, Ying
    Zhu, Liming
    Song, Zhengbo
    Xu, Nong
    Wang, Zhen
    Wang, Yanping
    Du, Yiqun
    Jing, Deqiang
    Chen, Dinglu
    Qu, Qiaofeng
    Zhao, Xiwen
    Li, Wei
    Lu, Qiying
    Tian, Wenzhi
    Xu, Jianming
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [27] A phase II, multicenter, open-label study of [fam-] trastuzumab deruxtecan (DS 8201a) in subjects with HER2-expressing gastric cancer.
    Shitara, Kohei
    Bang, Yung-Jue
    Chung, Hyun Cheol
    Yabusaki, Hiroshi
    Iwasa, Satoru
    Sakai, Daisuke
    Muro, Kei
    Sugimoto, Naotoshi
    Yasui, Hisateru
    Gamoh, Makio
    Murakawa, Yasuko
    Negoro, Yuji
    Nishina, Tomohiro
    Hosaka, Hisashi
    Omuro, Yasushi
    Kawaguchi, Yoshinori
    Sugihara, Masahiro
    Saito, Kaku
    Dalal, Rita
    Yamaguchi, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [28] DS-8201a, a HER2-targeting antibody-drug conjugate, to elicit immune responses and benefits in combination with an anti-PD-1 antibody.
    Iwata, Tomomi Nakayama
    Ishii, Chiaki
    Ogitani, Yusuke
    Wada, Teiji
    Agatsuma, Toshinori
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [29] Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
    Meric-Bernstam, Funda
    Calvo, Emiliano
    Lee, Keun Seok
    Moreno, Victor
    Park, Yeon Hee
    Rha, Sun Young
    Chalasani, Pavani
    Zhong, Wei
    Zhou, Li
    Pirie-Shepherd, Steven
    Leung, Abraham C. F.
    Curigliano, Giuseppe
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (10) : 1191 - 1203
  • [30] A phase 1 study of zanidatamab monotherapy in Japanese patients with metastatic or unresectable HER2-expressing cancers
    Doi, T.
    Muro, K.
    Nishina, T.
    Yamamoto, N.
    Yang, L.
    Grim, J.
    Koyama, T.
    ANNALS OF ONCOLOGY, 2024, 35 : S1318 - S1319
12345